chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 0.5
Sex: F
Vaccine: HEP
Symptoms: Incorrect dose administered, Product administered to patient of inappropriate age
Clinical narrative: 6 month old patient received an adult dose of engerix-b; 6 month old patient received an adult dose of engerix-b; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 6-month-old female patient who received HBV (Engerix B adult) (batch number 3X937, expiry date 07-DEC-2025) for prophylaxis.   On 02-FEB-2024, the patient received the 3rd dose of Engerix B adult. On 02-FEB-2024, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: 6 month old patient received an adult dose of engerix-b) and accidental overdose (Verbatim: 6 month old patient received an adult dose of engerix-b). The outcome of the adult product administered to child and accidental overdose were unknown.   Additional Information: GSK Receipt Date: 05-FEB-2024 The nurse reported that the 6 month old patient received an adult dose of engerix-b inadvertently, which led to adult product administered to child and accidental overdose. The reporter consented to the follow up.; Sender's Comments:  US-GSK-US2024016210:Same reporter/ Diffrent patient US-GSK-US2024016212:Same reporter/Diffrent aptient
Age: 1.0
Sex: F
Vaccine: TDAP
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: patient received Boostrix instead of Daptacel; a 15 month old patient Boostrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a 15-month-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number 25A2F, expiry date 19-JAN-2026) for prophylaxis.   On 02-FEB-2024, the patient received Boostrix. On 02-FEB-2024, an unknown time after receiving Boostrix, the patient experienced wrong vaccine administered (Verbatim: patient received Boostrix instead of Daptacel) and inappropriate age at vaccine administration (Verbatim: a 15 month old patient Boostrix). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 08-FEB-2024 The nurse reported a 15 month old female patient was ordered to receive Daptacel, however they were administered Boostrix instead which led to vaccine administered and inappropriate age at vaccine administration. The reporter consented to follow up. The vaccine administration facility is the same as primary reporter. The case is linked with US2024017846, same reporter.; Sender's Comments:  US-GSK-US2024017846:2 of 2 patient (Different patient/ same product)
Age: 0.17
Sex: F
Vaccine: RV1
Symptoms: Regurgitation, Underdose
Clinical narrative: threw it all up; Rotarix was administered to a patient and she threw it all up.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of regurgitation of medication in a 2-month-old female patient who received Rota (Rotarix lyophilized formulation) (batch number 735K2, expiry date 11-OCT-2025) for prophylaxis.   On 09-FEB-2024, the patient received Rotarix lyophilized formulation (oral). On 09-FEB-2024, less than a day after receiving Rotarix lyophilized formulation, the patient experienced regurgitation of medication (Verbatim: threw it all up) and accidental underdose (Verbatim: Rotarix was administered to a patient and she threw it all up.). The outcome of the regurgitation of medication and accidental underdose were unknown.   It was unknown if the reporter considered the regurgitation of medication to be related to Rotarix lyophilized formulation and Rotarix Oral Applicator Device.     It was unknown if the company considered the regurgitation of medication to be related to Rotarix lyophilized formulation and Rotarix Oral Applicator Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt date: 09-FEB-2024 A reporter reported that Rotarix was administered to a patient, and she threw it all up which led to accidental underdose. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up by postal.
Age: 79.0
Sex: F
Vaccine: FLU4
Symptoms: Extra dose administered, No adverse event
Clinical narrative: received 2 doses of fluzone high dose on the same day (one in the clinic and one in the pharmacy) with no reported adverse event; Initial information received on 07-Feb-2024 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 79-year-old female patient who received 2 doses of influenza quadrival A-B high dose HV vaccine [Fluzone High-Dose Quadrivalent] on the same day (one in the clinic and one in the pharmacy) with no reported adverse event.  The patient had no medical history, concomitant disease or risk factor.    On 24-Jan-2024, the patient received 2 dosage forms of suspect influenza quadrival A-B high dose HV vaccine, Suspension for injection in pre-filled syringe (lot number: UT8131CA; expiry date: unknown) via intramuscular route in unknown administration site for Prophylactic vaccination (immunization), on the same day (one in the clinic and one in the pharmacy) with no reported adverse event (extra dose administered) (same day latency).  There were no lab data/results available.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 1.0
Sex: F
Vaccine: HIBV
Symptoms: No adverse event, Product preparation error
Clinical narrative: gave a patient ACT-HIB using a different diluent with no reported adverse event; gave a patient ACT-HIB using a different diluent with no reported adverse event; Initial information received on 02-Feb-2024 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 12 months old female patient who was administered HIB (PRP/T) VACCINE [ACT-HIB] using a different diluent with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Measles Vaccine, Mumps Vaccine, Rubella Vaccine (MMR) for Prophylactic vaccination; Varicella Zoster Vaccine (Varicella vaccine) for Prophylactic vaccination; and Hepatitis A vaccine (Hepatitis A) for Prophylactic vaccination.  On 31-Jan-2024, the patient received 0.5 ml dose (dose 4) (frequency: once; strength: standard) of suspect HIB (PRP/T) vaccine Powder and solvent for solution for injection of lot UJ862AA and expiry: 24-Mar-2024 via intramuscular route in the left thigh for immunization.  On 31-Jan-2024, the patient was administered HIB (PRP/T) vaccine using a different diluent with no reported adverse event (product preparation error) (poor quality product administered) (latency: same day).  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 62.0
Sex: F
Vaccine: RAB
Symptoms: Blood glucose abnormal, Confusional state, Ear congestion, Head discomfort, Magnetic resonance imaging normal
Clinical narrative: transient global amnesia; migraines; she can forgot something; little bit confused; stuffy ears; stuffy feeling in her head; Initial information received on 08-Feb-2024 regarding an unsolicited valid  serious case received from a consumer/non-health care professional.  This case involves a 62 years old female patient who experienced transient global amnesia, stuffy ears, stuffy feeling in her head and migraines after receiving RABIES (HDC) vaccine [IMOVAX RABIES].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 23-Jan-2024, the patient received a dose 1 of suspect RABIES (HDC) VACCINE (Powder and solvent for suspension for injection) lot number not reported via unknown route in unknown administration site. On 26-Jan-2024 she also received a dose 2 of the same vaccine  with an unknown batch number via unknown route in unknown administration site. On 30-Jan-2024 she also received a dose 3 of the same vaccine  with an unknown strength, expiry date, batch number via unknown route in unknown administration site for Immunization. The information on batch number was requested.  On an unknown date the patient developed migraines (migraine) (unknown latency) following the administration of RABIES (HDC) VACCINE. On 01-FEB-2024 the patient developed stuffy ears (ear congestion) and stuffy feeling in her head (head discomfort) 9 days following the administration of RABIES (HDC) VACCINE. On 03-FEB-2024 the patient developed transient global amnesia , she can forgot something (memory impairment) and little bit confused (confusional state) 11 days following the administration of RABIES (HDC) VACCINE.  Relevant laboratory test results included: Blood test - On an unknown date:  [blood work was also normal except for glucose] Magnetic resonance imaging - On an unknown date:  [Normal]  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the events (stuffy ears, transient global amnesia, migraines, stuffy feeling in her head, she can forgot something, little bit confused).  At time of reporting, the outcome was Unknown for all the events.  Seriousness Criteria : The patient was hospitalized on Saturday, February 3rd about midday and discharged around 9:30 the next morning on the 04-Feb-2024 (transient global amnesia).; Sender's Comments: Sanofi Company Comment dated 12-Feb-2024 : This case involves a 62 years old female patient who experienced transient global amnesia, stuffy ears, stuffy feeling in her head and migraines after receiving RABIES (HDC) vaccine [IMOVAX RABIES]. Further information regarding Past medical history, concurrent condition, concomitant medication and tolerance, allergic history excluding alternative etiologies for the reported events are needed to fully assess this case. Based upon the reported information, the role of a vaccine cannot be assessed.
Age: 62.0
Sex: F
Vaccine: RAB
Symptoms: Memory impairment, Migraine, Transient global amnesia
Clinical narrative: transient global amnesia; migraines; she can forgot something; little bit confused; stuffy ears; stuffy feeling in her head; Initial information received on 08-Feb-2024 regarding an unsolicited valid  serious case received from a consumer/non-health care professional.  This case involves a 62 years old female patient who experienced transient global amnesia, stuffy ears, stuffy feeling in her head and migraines after receiving RABIES (HDC) vaccine [IMOVAX RABIES].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 23-Jan-2024, the patient received a dose 1 of suspect RABIES (HDC) VACCINE (Powder and solvent for suspension for injection) lot number not reported via unknown route in unknown administration site. On 26-Jan-2024 she also received a dose 2 of the same vaccine  with an unknown batch number via unknown route in unknown administration site. On 30-Jan-2024 she also received a dose 3 of the same vaccine  with an unknown strength, expiry date, batch number via unknown route in unknown administration site for Immunization. The information on batch number was requested.  On an unknown date the patient developed migraines (migraine) (unknown latency) following the administration of RABIES (HDC) VACCINE. On 01-FEB-2024 the patient developed stuffy ears (ear congestion) and stuffy feeling in her head (head discomfort) 9 days following the administration of RABIES (HDC) VACCINE. On 03-FEB-2024 the patient developed transient global amnesia , she can forgot something (memory impairment) and little bit confused (confusional state) 11 days following the administration of RABIES (HDC) VACCINE.  Relevant laboratory test results included: Blood test - On an unknown date:  [blood work was also normal except for glucose] Magnetic resonance imaging - On an unknown date:  [Normal]  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the events (stuffy ears, transient global amnesia, migraines, stuffy feeling in her head, she can forgot something, little bit confused).  At time of reporting, the outcome was Unknown for all the events.  Seriousness Criteria : The patient was hospitalized on Saturday, February 3rd about midday and discharged around 9:30 the next morning on the 04-Feb-2024 (transient global amnesia).; Sender's Comments: Sanofi Company Comment dated 12-Feb-2024 : This case involves a 62 years old female patient who experienced transient global amnesia, stuffy ears, stuffy feeling in her head and migraines after receiving RABIES (HDC) vaccine [IMOVAX RABIES]. Further information regarding Past medical history, concurrent condition, concomitant medication and tolerance, allergic history excluding alternative etiologies for the reported events are needed to fully assess this case. Based upon the reported information, the role of a vaccine cannot be assessed.
Age: 0.33
Sex: M
Vaccine: HIBV
Symptoms: No adverse event, Product storage error
Clinical narrative: shipment of vaccines had been in transit too long with no reported adverse event.; one of the affected vaccines, an ActHib single-dose vial, was administered to a patient with no reported adverse event; Initial information received on 08-Feb-2024 regarding an unsolicited valid  non-serious case received from a other health professional.  This case reports shipment of vaccines had been in transit too long and one of the affected vaccines, an HIB (PRP/T) VACCINE [ACT-HIB] single-dose vial, was administered to a  4 months old male patient with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Rotavirus Vaccine Live Reassort Oral 5V (Rotateq); Polio Vaccine and Pneumococcal Vaccine CONJ 20V (CRM197) (Prevnar 20) for Prophylactic Vaccination.  On an Unknown date it was reported that shipment of vaccines had been in transit too long and should be returned to Sanofi Pasteur Customer Service (product storage error) (Latency: Unknown).  On 07-Feb-2024, the patient had received a dose of 0.5 ml (dose: 2)  suspect HIB (PRP/T) Vaccine (Powder and solvent for solution for injection) (lot: UJ992AA; strength not reported) via intramuscular route in the left thigh for Immunization (poor quality product administered) (Latency: same day)  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive and Regulatory Authority Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 4.0
Sex: M
Vaccine: DTAP
Symptoms: Hyperaesthesia, Injection site erythema, Injection site induration, Injection site warmth
Clinical narrative: Left thigh with erythema patch around 5-6 cm w/warmth and induration, no fluctuation. PO Clindamycin 75mg/5mL, take 8 mL 3 x day for 10 days. Mupirocin oint. 2% apply 3x day for 10 days. On third day, pt reported improvement, walks and runs well but prefers not to touch site
Age: 2.67
Sex: M
Vaccine: VARCEL
Symptoms: Pyrexia, Rash vesicular, Varicella virus test
Clinical narrative: Pt seen today 2/13/24 for rash and fever started 2/11/24, swabbed for varicella d/t symptoms. Pt received a recent varicella vaccine on 2/2/24. Reporting due to recieving a live vaccine recently and being patient's 1st vaccine. Rash consistent with varicella. Pt swabbed pending lab result.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT VACCINATED AFTER VIABILITY DATE
Age: 29.0
Sex: F
Vaccine: MMR
Symptoms: Chest discomfort, Electrocardiogram abnormal, Posture abnormal, Pruritus, Respiratory arrest
Clinical narrative: Patient is a 29 y.o. female in acute distress presenting with symptoms of an allergic reaction in the context of receiving the MMR vaccine 20 minutes prior to arrival.  Patient was in respiratory distress on initial presentation to the ED with tachycardia, pruritus, urticaria, and chest tightness.  Tripoding and retractions present.  Post-treatment, breath sounds equal bilaterally without wheezes, rales, or rhonchi.   EKG shows sinus tachycardia.  No STEMI or arrhythmia.   Patient acutely managed with IM Epinephrine, IV 50 mg Benadryl, IV solumedrol, and IV Pepcid.  Symptoms improving.     Will continue to monitor patient in ED for 4-6 hours.  Vitals stable currently.   During the course of patient's ED visit, BP dropped to 84/45 mmHg.  Received 1L IV NS which stabilized her BP.   Discharged 4.5hrs after arrival without any further complications.
Age: 29.0
Sex: F
Vaccine: MMR
Symptoms: Sinus tachycardia, Tachycardia, Urticaria, Use of accessory respiratory muscles
Clinical narrative: Patient is a 29 y.o. female in acute distress presenting with symptoms of an allergic reaction in the context of receiving the MMR vaccine 20 minutes prior to arrival.  Patient was in respiratory distress on initial presentation to the ED with tachycardia, pruritus, urticaria, and chest tightness.  Tripoding and retractions present.  Post-treatment, breath sounds equal bilaterally without wheezes, rales, or rhonchi.   EKG shows sinus tachycardia.  No STEMI or arrhythmia.   Patient acutely managed with IM Epinephrine, IV 50 mg Benadryl, IV solumedrol, and IV Pepcid.  Symptoms improving.     Will continue to monitor patient in ED for 4-6 hours.  Vitals stable currently.   During the course of patient's ED visit, BP dropped to 84/45 mmHg.  Received 1L IV NS which stabilized her BP.   Discharged 4.5hrs after arrival without any further complications.
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT VACCINATED AFTER VIABILITY DATE
Age: 62.0
Sex: F
Vaccine: RSV
Symptoms: Chills, Fatigue, Nasopharyngitis, Pain, Pyrexia
Clinical narrative: The day after the administered vaccine, I felt like I had a cold for about a week and  onset of chronic fatigue.  About three weeks later, I began having  intermittent bouts of chills, fevers, exhaustion, and body aches.  Episodes occur about once every 7-9 days and last for about 6-7 hours.   Fevers are in range of 100-101 degrees F.    The next day, I feel okay again.  As of today, 2/14/24, I have experienced four of these episodes.   I went to my primary care physician who initially thought I may have a sinus infection, which turned out not to be the case.  As these symptoms continued to plague me, the conclusion was drawn that this is related to an adverse experience with my RSV vaccine received on 12/11/23.  No treatment administered at this time.  Doctor suggested that I will likely just have to wait this out to resolve.
Age: 1.5
Sex: F
Vaccine: DTAPIPV
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Patient received Kinrix instead on Infanrix
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Exposure to SARS-CoV-2, SARS-CoV-2 test
Clinical narrative: No symptoms but exposed to COVID
Age: 80.0
Sex: F
Vaccine: RSV
Symptoms: Asthenia, Fatigue, Malaise
Clinical narrative: felt ill - weak and tired
Age: 67.0
Sex: F
Vaccine: RSV
Symptoms: Dyspnoea, Fatigue, Headache, Oropharyngeal pain
Clinical narrative: Fatigue, H/a, sore throat, SOB (only one time)
Age: 0.75
Sex: M
Vaccine: FLUC4
Symptoms: Extra dose administered
Clinical narrative: Patient was given an additional dose of flu vaccine.  Second dose was administered on 12/14/23 Lot#370673 exp: 6/30/24 but not recorded in chart.  Therefore, when patient arrived for visit on 2/5/24,  a third dose of flu  was administered.
Age: 9.0
Sex: M
Vaccine: HPV9
Symptoms: Injection site swelling
Clinical narrative: Significant swelling at the injection site, right deltoid
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Neck pain, Vertigo
Clinical narrative: vertigo, nausea, bad neck pain especially at base if neck, temple headache, fatigue
Age: 71.0
Sex: F
Vaccine: COVID19, FLUA4, RSV
Symptoms: Injection site pain, Injection site reaction
Clinical narrative: LEFT ARM GOT RED DOWN TO ELBOW, STILL HAS PAIN IN LEFT UPPER ARM MUSCLE
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Cataplexy, Colonoscopy, Computerised tomogram, Endoscopy, General physical health deterioration
Clinical narrative: Immediately After  covid 19 vaccination I deteriorated rapidly and continue to.  I was diagnosed with severe narcolepsy with Cataplexy, migraines,  extreme light sensitivity, uncontrollable high blood pressure,  irritable bowel syndrome,  currently being tested for hypermobile Ehlers danlos syndrome.  I?ve lost the ability to work, I?m not allowed to drive anymore,  I lost everything. My body constantly is in agonizing pain.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Hypertension, Immediate post-injection reaction, Impaired driving ability, Impaired work ability, Irritable bowel syndrome
Clinical narrative: Immediately After  covid 19 vaccination I deteriorated rapidly and continue to.  I was diagnosed with severe narcolepsy with Cataplexy, migraines,  extreme light sensitivity, uncontrollable high blood pressure,  irritable bowel syndrome,  currently being tested for hypermobile Ehlers danlos syndrome.  I?ve lost the ability to work, I?m not allowed to drive anymore,  I lost everything. My body constantly is in agonizing pain.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Laboratory test, Magnetic resonance imaging, Migraine, Narcolepsy, Pain
Clinical narrative: Immediately After  covid 19 vaccination I deteriorated rapidly and continue to.  I was diagnosed with severe narcolepsy with Cataplexy, migraines,  extreme light sensitivity, uncontrollable high blood pressure,  irritable bowel syndrome,  currently being tested for hypermobile Ehlers danlos syndrome.  I?ve lost the ability to work, I?m not allowed to drive anymore,  I lost everything. My body constantly is in agonizing pain.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Photophobia, Sleep study
Clinical narrative: Immediately After  covid 19 vaccination I deteriorated rapidly and continue to.  I was diagnosed with severe narcolepsy with Cataplexy, migraines,  extreme light sensitivity, uncontrollable high blood pressure,  irritable bowel syndrome,  currently being tested for hypermobile Ehlers danlos syndrome.  I?ve lost the ability to work, I?m not allowed to drive anymore,  I lost everything. My body constantly is in agonizing pain.
Age: 37.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Diarrhoea, Dysstasia, Gait inability, Pain in extremity, Vomiting
Clinical narrative: Had vaccine administered at 12:30 pm, fell asleep a 2:30 pm and woke up to vomit. Proceeded to vomit 8 or 9 times over the course of several hours and intense joint pain in lower extremities. I could not stand or walk, instead crawling to my trash can to vomit or the bathroom to unload the diarrhea. It literally felt like I had consumed a large quantity of alcohol and was now trying expel it.
Age: 37.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Diarrhoea, Dysstasia, Feeding disorder, Hangover
Clinical narrative: Had vaccine administered at 12:30 pm, fell asleep a 2:30 pm and woke up to vomit. Proceeded to vomit 8 or 9 times over the course of several hours and intense joint pain in lower extremities. I could not stand or walk, instead crawling to my trash can to vomit or the bathroom to unload the diarrhea. It literally felt like I had consumed a large quantity of alcohol and was now trying expel it.
Age: 37.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Headache, Pyrexia, Vomiting
Clinical narrative: Had vaccine administered at 12:30 pm, fell asleep a 2:30 pm and woke up to vomit. Proceeded to vomit 8 or 9 times over the course of several hours and intense joint pain in lower extremities. I could not stand or walk, instead crawling to my trash can to vomit or the bathroom to unload the diarrhea. It literally felt like I had consumed a large quantity of alcohol and was now trying expel it.
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Adenovirus test, Alanine aminotransferase normal, Albumin globulin ratio decreased, Anion gap, Aspartate aminotransferase normal
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Basophil count decreased, Basophil percentage decreased, Bilirubin urine, Bladder catheterisation, Blood albumin decreased
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Blood alkaline phosphatase normal, Blood bilirubin decreased, Blood calcium decreased, Blood chloride normal, Blood creatinine normal
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Blood glucose normal, Blood potassium increased, Blood sodium decreased, Blood urea decreased, Blood urine absent
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Bordetella test negative, C-reactive protein increased, Carbon dioxide decreased, Chlamydia test negative, Chromaturia
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Conjunctivitis, Coronavirus test negative, Cough, Cytomegalovirus test, Enterovirus test negative
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Eosinophil count decreased, Eosinophil percentage decreased, Epstein-Barr virus antibody, Globulins increased, Glucose urine absent
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Haematocrit normal, Haemoglobin decreased, Human metapneumovirus test, Human rhinovirus test, Immature granulocyte count
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Influenza A virus test negative, Influenza B virus test, Influenza virus test negative, Lymphadenopathy, Lymphocyte count
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Lymphocyte percentage decreased, Mean cell haemoglobin concentration normal, Mean cell haemoglobin decreased, Mean cell volume decreased, Mean platelet volume increased
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Monocyte count increased, Monocyte percentage increased, Mycoplasma test negative, N-terminal prohormone brain natriuretic peptide increased, Neutrophil count increased
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Nitrite urine absent, Nucleated red cells, Platelet count normal, Protein total decreased, Protein urine
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Pyrexia, Rash, Rash maculo-papular, Red blood cell count decreased, Red blood cell sedimentation rate increased
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Red blood cells urine negative, Red cell distribution width, Respiratory syncytial virus test negative, Respiratory tract congestion, Respirovirus test negative
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Rubulavirus test negative, SARS-CoV-2 RNA, SARS-CoV-2 test negative, Serum ferritin increased, Specific gravity urine
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Urinary sediment present, Urine abnormality, Urine analysis abnormal, Urine ketone body present, Urobilinogen urine
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 1.0
Sex: F
Vaccine: MMR, UNK
Symptoms: White blood cell count increased, White blood cells urine negative, White blood cells urine positive, pH urine normal
Clinical narrative: Developed fever on 2/6, then congestion and R sided cervical lymphadenopathy on ~2/8, developed maculopapular rash that started on face and spread throughout her body on 2/9-2/10 also with more cough and mild conjunctivitis around that time.  Admitted on 12/12 in the evening due to concern for Kawasaki disease (evaluation negative). Fevers better on 2/14 (went nearly 24 hours without fever) and rash essentially resolved/faded
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Ataxia, Deafness, Disorientation, Echocardiogram, Electrocardiogram
Clinical narrative: DISORIENTATION, HEARING LOSS, VISUAL DISTURBANCE, ATAXIA, SMALL FIBER NEUROPATHY
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Laboratory test, Small fibre neuropathy, Visual impairment
Clinical narrative: DISORIENTATION, HEARING LOSS, VISUAL DISTURBANCE, ATAXIA, SMALL FIBER NEUROPATHY
Age: 5.0
Sex: F
Vaccine: COVID19, FLU4
Symptoms: No adverse event, Product administered to patient of inappropriate age, Underdose
Clinical narrative: No adverse reaction.  Patient under vaccinated.  Used the 6mo-4yr dosage instead of the 5yr-11yr dosage.
Age: 91.0
Sex: F
Vaccine: RSV
Symptoms: Body temperature increased, General physical health deterioration, Hyperglycaemia
Clinical narrative: hyperglycemia, elevated temp, had been declining, possible aspiration, was on hospice but not actively dying, CTB1/16/2024
Age: 78.0
Sex: M
Vaccine: RSV, VARZOS
Symptoms: Chest pain, Dizziness, Fatigue, Headache, Injection site pain
Clinical narrative: Dizziness, extreme fatigue, muscle ache, slight chest pain, headache lasting about 2 days.  Typical soreness at injection site still present to a lesser degree after 5 days.
Age: 78.0
Sex: M
Vaccine: RSV, VARZOS
Symptoms: Myalgia
Clinical narrative: Dizziness, extreme fatigue, muscle ache, slight chest pain, headache lasting about 2 days.  Typical soreness at injection site still present to a lesser degree after 5 days.
Age: 92.0
Sex: U
Vaccine: RSV
Symptoms: Body temperature increased, Oxygen saturation decreased, Respiratory disorder
Clinical narrative: increased respiratory issues, decreased spo2, increased temp, CTB 1/18/2024
Age: 1.67
Sex: F
Vaccine: COVID19
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: Vaccine undiluted, full vial administered
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood test, Chest pain, Confusional state, Echocardiogram, Electrocardiogram
Clinical narrative: FIRST PFIZER 5/20/2021 SECOND PFIZER 6/6/2021 ONE MONTH LATER DEVELOPED CONFUSION, TINNITUS, SMALL FIBER NEUROPATHY, CHEST PAIN, PLEURODYNIA, POTS
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Immunisation reaction, Magnetic resonance imaging, Pleuritic pain, Postural orthostatic tachycardia syndrome, Small fibre neuropathy
Clinical narrative: FIRST PFIZER 5/20/2021 SECOND PFIZER 6/6/2021 ONE MONTH LATER DEVELOPED CONFUSION, TINNITUS, SMALL FIBER NEUROPATHY, CHEST PAIN, PLEURODYNIA, POTS
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: FIRST PFIZER 5/20/2021 SECOND PFIZER 6/6/2021 ONE MONTH LATER DEVELOPED CONFUSION, TINNITUS, SMALL FIBER NEUROPATHY, CHEST PAIN, PLEURODYNIA, POTS
Age: 30.0
Sex: F
Vaccine: COVID19-2
Symptoms: Contusion, Platelet count decreased, Thrombocytopenia
Clinical narrative: Thrombocytopenia with bruising
Age: 96.0
Sex: F
Vaccine: RSV
Symptoms: Livedo reticularis, Unresponsive to stimuli
Clinical narrative: not responding to verbal or tactile stimuli. unable to obtain pulse oximetry. Mottling noted to the lower extremities. CTB 1/14/2024
Age: 82.0
Sex: F
Vaccine: PNC20, VARZOS
Symptoms: Dizziness, Injection site erythema, Injection site pain, Injection site swelling, Muscular weakness
Clinical narrative: Redness, pain,swelling at site, dizziness, muscle weaknesss,nausea,lightheadedness. Started approximately at !!.00 pm on February 12. Started taking 2  acetaminophen 500 mg,  every four hours. This helped with the muscle weakness. Continuing taking 2 acetaminophen 500 mg to enable me to function.
Age: 82.0
Sex: F
Vaccine: PNC20, VARZOS
Symptoms: Nausea
Clinical narrative: Redness, pain,swelling at site, dizziness, muscle weaknesss,nausea,lightheadedness. Started approximately at !!.00 pm on February 12. Started taking 2  acetaminophen 500 mg,  every four hours. This helped with the muscle weakness. Continuing taking 2 acetaminophen 500 mg to enable me to function.
Age: 79.0
Sex: M
Vaccine: RSV
Symptoms: Breath sounds abnormal, Drooling, Dysarthria, Dyspnoea, Facial paralysis
Clinical narrative: change in condition, Resident lethargic, opens eyes to name, speech slurred, left facial drooping\drooling. Lungs with rhonchi left fields, right fields diminished. resp labored at times 20 O2 sat 85%, O2 at 2L\min started after approx 3mins sat 89-91%, left arm cold\pale,
Age: 79.0
Sex: M
Vaccine: RSV
Symptoms: General physical condition abnormal, Lethargy, Pallor, Peripheral coldness, Rhonchi
Clinical narrative: change in condition, Resident lethargic, opens eyes to name, speech slurred, left facial drooping\drooling. Lungs with rhonchi left fields, right fields diminished. resp labored at times 20 O2 sat 85%, O2 at 2L\min started after approx 3mins sat 89-91%, left arm cold\pale,
Age: 78.0
Sex: M
Vaccine: RSV
Symptoms: Breath sounds abnormal, Cough, Discomfort, Malaise
Clinical narrative: Resident is s/p RSV vaccine day #3. Resident complained of generalized discomfort and not feeling well. VS 100.6-84-20-134/76-96% on RA. Respirations are even and unlabored. Lung sounds are clear but diminished at bases. Occasional dry cough noted.
Age: 67.0
Sex: U
Vaccine: COVID19, FLUA4, PNC20
Symptoms: Extra dose administered, Injection site pain
Clinical narrative: There were no adverse effects experienced or reported by patient. When the Prevnar20 was logged into IZ (after the fact) we noticed that the patient had already received a Prevnar20 previously (12/15/22) from another pharmacy. I called the patient to check on her and to let her know what happened. The patient denies having the first administration of Prevnar20. She said she that her dr had recently suggested that she get this immunization so she did just that. The patient said the only side effect she was experiencing was the common soreness at the injection site.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Breakthrough COVID-19, SARS-CoV-2 RNA, SARS-CoV-2 test positive
Clinical narrative: HOSPITALIZATION RELATED TO COVID-19 FOLLOWING COMPLETION OF PRIMARY VACCINE SERIES
Age: 0.33
Sex: F
Vaccine: RV5
Symptoms: Diarrhoea
Clinical narrative: Loose stools/diarrhea x2 months post second dose of rotavirus vaccine
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Anxiety, Blood glucose abnormal, Breakthrough COVID-19, Cataract, Chronic obstructive pulmonary disease
Clinical narrative: HOSPITALIZATION RELATED TO COVID-19 FOLLOWING COMPLETION OF PRIMARY VACCINE SERIES
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Deafness bilateral, Dementia, Gait disturbance, Glucose tolerance impaired, Hyperlipidaemia
Clinical narrative: HOSPITALIZATION RELATED TO COVID-19 FOLLOWING COMPLETION OF PRIMARY VACCINE SERIES
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Hypertension, Hypogonadism male, Nervous system disorder, Neuropathy peripheral, Obesity
Clinical narrative: HOSPITALIZATION RELATED TO COVID-19 FOLLOWING COMPLETION OF PRIMARY VACCINE SERIES
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Oedema, Osteoarthritis, Peripheral arterial occlusive disease, Psoriasis, SARS-CoV-2 RNA
Clinical narrative: HOSPITALIZATION RELATED TO COVID-19 FOLLOWING COMPLETION OF PRIMARY VACCINE SERIES
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Vertigo positional
Clinical narrative: HOSPITALIZATION RELATED TO COVID-19 FOLLOWING COMPLETION OF PRIMARY VACCINE SERIES
Age: 11.0
Sex: M
Vaccine: MENB, TDAP
Symptoms: No adverse event, Wrong product administered
Clinical narrative: PATIENT WAS GIVEN A MEN B INSTEAD OF A MCV. PATIENT HAD NO ADVERSE REACTIONS. THE PROVIDER CALLED MOTHER AND SPOKE TO HER AND EXPLAINED THE SITUATION AND EDUCATED ON POSSIBLE REACTIONS TO THE VACCINE. MOTHER WAS ADVICED TO COME BACK IN 1 MONTH FOR THE CORRECT MCV VACCINE.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: ongoing left shoulder pain after receiving covid vaccine, has been doing physical therapy since 1/11/2024. Saw Dr. regarding the covid vaccine injury
Age: 71.0
Sex: F
Vaccine: PNC20
Symptoms: Headache, Injection site rash, Pain
Clinical narrative: Patient reports having body ache and pulsing headache after getting Prevnar 20 vaccine yesterday. Left arm arm developed rash near vaccine entry.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Breakthrough COVID-19, SARS-CoV-2 RNA, SARS-CoV-2 test positive
Clinical narrative: HOSPITALIZATION RELATED TO COVID-19 FOLLOWING COMPLETION OF PRIMARY VACCINE SERIES
Age: 33.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event
Clinical narrative: no adverse effects noted
Age: 52.0
Sex: F
Vaccine: FLUC4, UNK, VARZOS
Symptoms: Immunisation reaction
Clinical narrative: Adverse effect of vaccines and biological substances, init on 2024-01-29.
Age: 62.0
Sex: F
Vaccine: COVID19, VARZOS
Symptoms: Immunisation reaction
Clinical narrative: Adverse effect of vaccines and biological substances, init on 2024-01-31.
Age: 0.75
Sex: F
Vaccine: FLUC4
Symptoms: Rash
Clinical narrative: Rash and other nonspecific skin eruption on 2024-02-02.
Age: 4.0
Sex: F
Vaccine: MMRV
Symptoms: Rash
Clinical narrative: rash NOS on 2023-10-17.
Age: 64.0
Sex: F
Vaccine: PNC20, TD
Symptoms: Syncope
Clinical narrative: Fainting on 2023-11-03.
Age: 0.17
Sex: M
Vaccine: DTAPHEPBIP, PNC20, RV5, UNK
Symptoms: Vomiting
Clinical narrative: Vomiting NOS on 2024-01-29.
Age: 89.0
Sex: F
Vaccine: UNK
Symptoms: Balance disorder
Clinical narrative: Unsteadiness on feet on 2024-02-01.
Age: 59.0
Sex: F
Vaccine: VARZOS
Symptoms: Immunisation reaction
Clinical narrative: Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter on 2024-02-02.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, Bronchitis, Condition aggravated, Cough, Epistaxis
Clinical narrative: Worsening asthma symptoms,  sudden forceful cough, bronchitis, bloody nose, yellow phlegm
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Sputum discoloured
Clinical narrative: Worsening asthma symptoms,  sudden forceful cough, bronchitis, bloody nose, yellow phlegm
Age: 70.0
Sex: F
Vaccine: RSV
Symptoms: Gait disturbance, Pain
Clinical narrative: Patient woke up with pain from their neck down to their ankle. Patient also said they had trouble walking. Patient took a tylenol but said it did not help much. The next morning when patient woke up they said they felt fine.
Age: 2.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: Patient given 0.5ml from SDV instead of 0.25ml. Child had NO adverse reaction  immediatley after or since. Reporter spoke with mother of child 02/14/24 who said, "she is her normal self, a bundle of energy".
Age: 93.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Loss of personal independence in daily activities
Clinical narrative: severe headache that limited daily activities
Age: 31.0
Sex: F
Vaccine: MMR
Symptoms: Erythema, Swelling, Tenderness
Clinical narrative: Swollen, red, tender
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT VACCINATED AFTER VIABILITY DATE.
Age: 24.0
Sex: F
Vaccine: UNK
Symptoms: Injection site pain, Injection site warmth
Clinical narrative: warm, tender patch of skin below injection site. treated with Motrin and Icepack. Will refer to MD if uncontrolled with tx options.
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hemiparesis, Hypoaesthesia, Injection site bruising, Injection site pain, Rash
Clinical narrative: approximately 4 hours after injection pt states her entire left side of her body "went numb" and felt weak. Symptom lasted a few hours and resolved on its own. Pt then developed a rash to her bil arms, chest, and head starting about 6 hours after vaccination. Rash is painful and itchy. No history of rash in lifetime prior to this. 10 days later, pt still has pain and bruising at injection site.
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash pruritic
Clinical narrative: approximately 4 hours after injection pt states her entire left side of her body "went numb" and felt weak. Symptom lasted a few hours and resolved on its own. Pt then developed a rash to her bil arms, chest, and head starting about 6 hours after vaccination. Rash is painful and itchy. No history of rash in lifetime prior to this. 10 days later, pt still has pain and bruising at injection site.